Riluzole

Generic Name: Riluzole

Brand Names: Exservan, Rilutek, Tiglutik, Riluzole Zentiva

Drug Type: Small Molecule

Chemical Formula: C_₈H_₅F_₃N_₂OS

CAS Number: 1744-22-5

Unique Ingredient Identifier: 7LJ087RS6F

Background: A glutamate antagonist (receptors, glutamate) used as an anticonvulsant (anticonvulsants) and to prolong the survival of patients with amyotrophic lateral sclerosis. Riluzole is marketed as Rilutek by Sanofi.

Indication: For the treatment of amyotrophic lateral sclerosis (ALS, Lou Gehrig's Disease)

Associated Conditions: Amyotrophic Lateral Sclerosis (ALS)

Clinical Trials

A Double-Blind Placebo Controlled Trial of Riluzole in Bipolar Depression

Phase 2

Completed

Conditions: Bipolar Disorder

Interventions: Other: Placebo
Drug: Riluzole

First Posted Date: 2006-09-14

Last Posted Date: 2017-04-11

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 94

Registration Number: NCT00376220

Locations: 🇺🇸
Johns Hopkins, Baltimore, Maryland, United States

Treatment of Refractory Schizophrenia With Riluzole

Not Applicable

Completed

Conditions: Schizophrenia
Schizoaffective

Interventions: Drug: Riluzole
Drug: Placebo

First Posted Date: 2006-09-12

Last Posted Date: 2019-12-09

Lead Sponsor: Yale University

Target Recruit Count: 34

Registration Number: NCT00375050

Locations: 🇺🇸
Yale Department of Psychiatry, New Haven, Connecticut, United States

Memantine for Disability in Amyotrophic Lateral Sclerosis (MEDALS)

Phase 2

Completed

Conditions: Amyotrophic Lateral Sclerosis

Interventions: Drug: Memantine (Ebixa)
Drug: Placebo
Drug: riluzole

First Posted Date: 2006-07-19

Last Posted Date: 2009-04-01

Lead Sponsor: University of Lisbon

Target Recruit Count: 63

Registration Number: NCT00353665

Locations: 🇵🇹
Department of Neurology - Hospital de Santa Maria, Lisbon, Portugal

Memantine or Riluzole Prophylaxis for Corticosteroid-induced Mood and Declarative Memory Changes

Phase 4

Terminated

Conditions: Mood
Memory Deficit

Interventions: Drug: Memantine
Drug: Riluzole

First Posted Date: 2006-01-27

Last Posted Date: 2013-04-23

Lead Sponsor: University of Texas Southwestern Medical Center

Target Recruit Count: 20

Registration Number: NCT00283309

Locations: 🇺🇸
UT Southwestern, Dallas, Texas, United States

Riluzole in Huntington's Disease

Phase 3

Completed

Conditions: Huntington Disease

First Posted Date: 2006-01-16

Last Posted Date: 2012-02-17

Lead Sponsor: Sanofi

Target Recruit Count: 537

Registration Number: NCT00277602

Riluzole to Treat Child and Adolescent Obsessive-Compulsive Disorder With or Without Autism Spectrum Disorders

Phase 2

Completed

Conditions: Autism
Developmental Disorder
Obsessive-Compulsive Disorder
Autism Spectrum Disorder
Asperger Disorder

Interventions: Drug: Placebo
Drug: Riluzole

First Posted Date: 2005-11-09

Last Posted Date: 2014-07-15

Lead Sponsor: National Institute of Mental Health (NIMH)

Target Recruit Count: 78

Registration Number: NCT00251303

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Neuroprotection and Natural History in Parkinson's Plus Syndromes (NNIPPS)

Phase 3

Terminated

Conditions: Multiple System Atrophy
Progressive Supranuclear Palsy

First Posted Date: 2005-09-21

Last Posted Date: 2005-12-15

Lead Sponsor: King's College London

Target Recruit Count: 800

Registration Number: NCT00211224

Locations: 🇬🇧
Institute of Psychiatry, King's College London, London, United Kingdom

Effect of Riluzole as a Symptomatic Approach in Patients With Chronic Cerebellar Ataxia

Phase 2

Completed

Conditions: Hereditary Ataxia
Multiple Sclerosis
Cerebellar Ataxia

Interventions: Other: placebo
Drug: Riluzole

First Posted Date: 2005-09-20

Last Posted Date: 2024-12-02

Lead Sponsor: S. Andrea Hospital

Target Recruit Count: 40

Registration Number: NCT00202397

Locations: 🇮🇹
S.Andrea Hospital - University of Rome "La Sapienza", Rome, Italy

Riluzole to Treat Depression in Bipolar Disorder

Phase 2

Terminated

Conditions: Bipolar Disorder

Interventions: Drug: Placebo
Drug: Riluzole

First Posted Date: 2003-02-07

Last Posted Date: 2019-04-25

Lead Sponsor: National Institute of Mental Health (NIMH)

Target Recruit Count: 19

Registration Number: NCT00054704

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Riluzole to Treat Major Depression

Phase 2

Completed

Conditions: Depression

First Posted Date: 2001-11-09

Last Posted Date: 2008-03-04

Lead Sponsor: National Institute of Mental Health (NIMH)

Target Recruit Count: 31

Registration Number: NCT00026052

Locations: 🇺🇸
National Institute of Mental Health (NIMH), Bethesda, Maryland, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy